Neo-adjuvant PIPAC and Systemic Chemotherapy in Management of Synchronous Peritoneal Metastasis From Gastric Cancer

Journal Title: Journal of Clinical Medical Research - Year 2023, Vol 4, Issue 3

Abstract

Introduction: Polycystic Ovarian Disorder (PCOD) is a prevalent endocrine illness in women of reproductive age. It has hormonal abnormalities, irregular menstrual cycles and tiny ovarian cysts. Lifestyle and food affect PCOD development and maintenance, coupled with Peritoneal metastasis from gastric cancer remains a major problem. The aim of our study is a retrospective analysis in two different groups with used PIPAC as neo-adjuvant management of synchronous peritoneal metastasis. Group A: 42 patients received as neo-adjuvant treatment 2 cycles of PIPAC (Doxorubicin 3 mgr/m2, cisplatin 10 mgr/m2) and 6 cycles of neo-adjuvant systemic chemotherapy with FLOT and we performed CRS+HIPEC (with cisplatin 80 mgr/m2, mitomycin 35 mgr/m2) for 90 min and 6 cycles of adjuvant systemic chemotherapy with FLOT. Group B: 26 patients received 4 cycles of neo-adjuvant systemic chemotherapy with FLOT, we performed CRS+HIPEC as Group A and 4 cycles of systemic chemotherapy with FLOT. For patients of Group A, the Median survival time is 46months.Group B patients had a median OS of 36 months. For patients of Group A, the Median Disease Time (DFS) was 37 months. Group B patients had a median DFS of 30 months. For each degree increase in the PCI pre score and for the same treatment group, the PCI posr score increases by 0.573 degrees. Group 2, for the same PCIpre score, have a 163% higher PCI posr score. On patients with singet ring cell adenocarcinoma there is a statistical significance difference in OS for PIPAC group. Patients of group A had a median OS of 26 months. For patients of group B, the median OS was 14 months. Morbidity and mortality in both groups are 53,4% and 4,7% for Group A and 44,5% and 5,5% for Group B respectively. The neo-adjuvant PIPAC with systemic chemotherapy might be a promising approach for patients with peritoneal metastasis from gastric cancer. PIPAC is a safe and well tolerated procedure.

Authors and Affiliations

Bohlooli M, Farmakis D, Saroyan H, Kazemi V, Noskova I, Omid R, Spiliotis J

Keywords

Related Articles

The Effects of Allogeneic cADSCs on an Experimental Ear Auricular Defect to Evaluate Cartilage Regeneration in a Canine Model

Objective: Ear is one of the most important organs of the auditory system and may fail as a result of trauma, tumors, or other diseases. Allograft transplantation of adult stem cells has been used as an excellent proce...

Somatic Comorbidities among Senior Schizophrenics: A Local Pilot Estimation

Introduction: Comorbidity between mental disorders and physical illnesses is the rule rather than the exception. Approaches to study the impact of comorbidity become challenging also due to lack of consensus about how...

Effect of Early Administration of Oropharyngeal Colostrum in Reducing Late Onset Neonatal Sepsis

Background: Early administration of colostrum by oropharyngeal route plays a tremendous role in preventing mortality and morbidity in preterm infants. The objective of this study was to determine if oropharyngeal adminis...

Microfracture and Hydrogel Scaffolds for the Treatment of Osteochondral Injuries of the Knee: Clinical Results at 4 Years Follow-Up

The aim of this study is to evaluate the outcomes of microfracture technique and novel hydrogel scaffold for the treatment of osteochondral injuries of the knee. Forty-one patients affected by grade III and IV osteocho...

Osmolality Threshold for Sickle Cell Erythrocyte Hemolysis

Background: The importance of fluid intake is well document as metabolic and physiological processes operate effectively in a homeostatic environment. Normal red cells are more resilient to changes in serum osmolality...

Download PDF file
  • EP ID EP722226
  • DOI http://dx.doi.org/10.46889/JCMR.2023.4307
  • Views 37
  • Downloads 0

How To Cite

Bohlooli M, Farmakis D, Saroyan H, Kazemi V, Noskova I, Omid R, Spiliotis J (2023). Neo-adjuvant PIPAC and Systemic Chemotherapy in Management of Synchronous Peritoneal Metastasis From Gastric Cancer. Journal of Clinical Medical Research, 4(3), -. https://europub.co.uk./articles/-A-722226